MIM
FMTX

MetLife Investment Management’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

MetLife Investment Management’s Portfolio FMTX Stock Details FMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18,921
Closed -$377K – 2875
2022
Q3 		$377K Buy
18,921
+4,638
+32% +$61.2K ﹤0.01% 1839
2022
Q2 		$98.4K Sell
14,283
-4,647
-25% -$32.6K ﹤0.01% 2715
2022
Q1 		$176K Buy
18,930
+6,986
+58% +$74.4K ﹤0.01% 2429
2021
Q4 		$170K Hold
11,944
– – ﹤0.01% 2158
2021
Q3 		$277K Hold
11,944
– – ﹤0.01% 1876
2021
Q2 		$297K Hold
11,944
– – ﹤0.01% 1894
2021
Q1 		$335K Buy
11,944
+4,910
+70% +$177K ﹤0.01% 1751
2020
Q4 		$245K Hold
7,034
– – ﹤0.01% 1860
2020
Q3 		$351K Buy
+7,034
New +$284K ﹤0.01% 1548

MetLife Investment Management's FMTX Position: Q4 2022 in Review

MetLife Investment Management sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 18,921 shares — an estimated $377K sold.

MetLife Investment Management first reported a position in FMTX in Q3 2020 and held it in 9 quarters. The position peaked at $377K in Q3 2022. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

  • MetLife Investment Management reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • MetLife Investment Management sold 18,921 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $377K.
  • MetLife Investment Management first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 9 quarters.
  • MetLife Investment Management's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $377K in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on MetLife Investment Management's 13F filing for Q4 2022, filed 15 Feb 2023.